Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients

✍ Scribed by Anna M. Russell; Jian Zhang; Judith Luz; Pierre Hutter; Pierre O. Chappuis; Claudine Rey Berthod; Philippe Maillet; Hansjakob Mueller; Karl Heinimann

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: French
• Weight: 112 KB
• Volume: 118
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.21470

✦ Synopsis

Abstract

In 10–30% of patients with classical familial adenomatous polyposis (FAP) and up to 90% of those with attenuated (<100 colorectal adenomas; AFAP) polyposis, no pathogenic germline mutation in the adenomatous polyposis coli (APC) gene can be identified (APC mutation‐negative). Recently, biallelic mutations in the base excision repair gene MYH have been shown to predispose to a multiple adenoma and carcinoma phenotype. This study aimed to (i) assess the MYH mutation carrier frequency among Swiss APC mutation‐negative patients and (ii) identify phenotypic differences between MYH mutation carriers and APC/MYH mutation‐negative polyposis patients. Seventy‐nine unrelated APC mutation‐negative Swiss patients with either classical (n = 18) or attenuated (n = 61) polyposis were screened for germline mutations in MYH by dHPLC and direct genomic DNA sequencing. Overall, 7 (8.9%) biallelic and 9 (11.4%) monoallelic MYH germline mutation carriers were identified. Among patients with a family history compatible with autosomal recessive inheritance (n = 45), 1 (10.0%) out of 10 classical polyposis and 6 (17.1%) out of 35 attenuated polyposis patients carried biallelic MYH alterations, 2 of which represent novel gene variants (p.R171Q and p.R231H). Colorectal cancer was significantly (p < 0.007) more frequent in biallelic mutation carriers (71.4%) compared with that of monoallelic and MYH mutation‐negative polyposis patients (0 and 13.8%, respectively). On the basis of our findings and earlier reports, MYH mutation screening should be considered if all of the following criteria are fulfilled: (i) presence of classical or attenuated polyposis coli, (ii) absence of a pathogenic APC mutation, and (iii) a family history compatible with an autosomal recessive mode of inheritance. © 2005 Wiley‐Liss, Inc.